A single nucleotide variant of human PARP1 determines response to PARP inhibitors

The introduction of novel cancer drugs and innovative treatments brings great hope for cancer patients, but also an urgent need to match drugs to suitable patients, since certain drugs that benefit one patient may actually harm others. The newly developed poly-ADP ribose polymerase (PARP) inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: Cashman, Rivki, Zilberberg, Alona, Priel, Avner, Philip, Hagit, Varvak, Alexander, Jacob, Avi, Shoval, Irit, Efroni, Sol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184601/
https://www.ncbi.nlm.nih.gov/pubmed/32352035
http://dx.doi.org/10.1038/s41698-020-0113-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184601/
https://www.ncbi.nlm.nih.gov/pubmed/32352035
http://dx.doi.org/10.1038/s41698-020-0113-2

Ejemplares similares